PROF

Profound Medical

4.04 USD
-0.23
5.39%
At close May 14, 4:00 PM EDT
After hours
4.24
+0.20
4.95%
1 day
-5.39%
5 days
-16.18%
1 month
-15.13%
3 months
-39.70%
6 months
-49.56%
Year to date
-48.86%
1 year
-50.79%
5 years
-66.80%
10 years
-59.11%
 

About: Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the image-guided ablation of diseased tissue utilizing its platform technologies and leveraging the healthcare system's existing imaging infrastructure. The company's product TULSA-PRO system combines real-time MRI, robotically driven transurethral sweeping-action thermal ultrasound with closed-loop temperature feedback control for the ablation of prostate tissue. The product is comprised of one-time-use devices and durable equipment that are used in conjunction with a customer's existing MRI scanner.

Employees: 142

0
Funds holding %
of 7,425 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

280% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 5

183% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 6

164% more call options, than puts

Call options by funds: $29K | Put options by funds: $11K

37% more capital invested

Capital invested by funds: $75M [Q3] → $103M (+$28.1M) [Q4]

18% more funds holding

Funds holding: 44 [Q3] → 52 (+8) [Q4]

7.4% more ownership

Funds ownership: 38.47% [Q3] → 45.86% (+7.4%) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q3] → 2 (+0) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$11
172%
upside
Avg. target
$11
172%
upside
High target
$11
172%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
Lake Street
Benjamin Haynor
0% 1-year accuracy
0 / 3 met price target
172%upside
$11
Buy
Maintained
23 Apr 2025

Financial journalist opinion

Based on 22 articles about PROF published over the past 30 days

Neutral
GlobeNewsWire
10 hours ago
Profound Medical Annual General and Special Meeting of Shareholders Voting Results
TORONTO, May 14, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce the voting results from its Annual General and Special Meeting of Shareholders that was held today (the “Meeting”). A total of 20,587,011 common shares, representing 68.5% of the common shares outstanding, were represented in person and by proxy at the Meeting.
Profound Medical Annual General and Special Meeting of Shareholders Voting Results
Neutral
Seeking Alpha
5 days ago
Profound Medical Corporation (PROF) Q1 2025 Earnings Conference Call Transcript
Profound Medical Corporation (NASDAQ:PROF ) Q1 2025 - Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Stephen Kilmer - Head IR Rashed Dewan - CFO Dr. Mathieu Burtnyk - COO Tom Tamberrino - Chief Commercial Officer Arun Menawat - CEO Conference Call Participants Ben Haynor - Lake Street Capital Markets John McAuley - Stifel Michael Freeman - Raymond James Scott McAuley - Paradigm Capital Operator Good day, and thank you for standing by. Welcome to the Profound Medical First Quarter 2025 Financial Results Conference Call.
Profound Medical Corporation (PROF) Q1 2025 Earnings Conference Call Transcript
Negative
Zacks Investment Research
6 days ago
Profound Medical (PROF) Reports Q1 Loss, Misses Revenue Estimates
Profound Medical (PROF) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.26 per share a year ago.
Profound Medical (PROF) Reports Q1 Loss, Misses Revenue Estimates
Positive
Zacks Investment Research
1 week ago
Strength Seen in Profound Medical (PROF): Can Its 8.3% Jump Turn into More Strength?
Profound Medical (PROF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Strength Seen in Profound Medical (PROF): Can Its 8.3% Jump Turn into More Strength?
Neutral
Accesswire
1 week ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Profound Medical Corp. - PROF
NEW YORK CITY, NY / ACCESS Newswire / May 3, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Profound Medical Corp. ("Profound" or the "Company") (NASDAQ:PROF). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Profound Medical Corp. - PROF
Neutral
Accesswire
1 week ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Profound Medical Corp. - PROF
NEW YORK, NY / ACCESS Newswire / May 2, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Profound Medical Corp. ("Profound" or the "Company") (NASDAQ:PROF). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Profound Medical Corp. - PROF
Neutral
Accesswire
1 week ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Profound Medical Corp. - PROF
Pomerantz LLP is investigating claims on behalf of investors of Profound Medical Corp. ("Profound" or the "Company") (NASDAQ:PROF). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Profound Medical Corp. - PROF
Neutral
GlobeNewsWire
2 weeks ago
Profound Medical to Participate in the 2025 Bloom Burton & Co. Healthcare Investor Conference
TORONTO, April 30, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that management will present an update on the Company's business at the 2025 Bloom Burton & Co. Healthcare Investor Conference on Tuesday, May 6, 2025 at 1:30 p.m. Eastern Time at the Metro Toronto Convention Centre.
Profound Medical to Participate in the 2025 Bloom Burton & Co. Healthcare Investor Conference
Neutral
Accesswire
2 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Profound Medical Corp. - PROF
NEW YORK, NY / ACCESS Newswire / April 30, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Profound Medical Corp. ("Profound" or the "Company") (NASDAQ:PROF). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Profound Medical Corp. - PROF
Neutral
GlobeNewsWire
2 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Profound Medical Corp. - PROF
NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Profound Medical Corp. (“Profound” or the “Company”) (NASDAQ: PROF).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Profound Medical Corp. - PROF
Charts implemented using Lightweight Charts™